Novartis is doubling down on Kisqali, its breast cancer treatment, after reporting a solid 10% increase in quarterly revenue. The Swiss pharmaceutical giant sees Kisqali as a future blockbuster, especially after new trial data showed a significant survival benefit. The company’s overall growth was supported by strong performance across its oncology and immunology segments. CEO Vas Narasimhan highlighted Novartis’s pivot toward high-value, innovative medicines and confirmed full-year guidance. The market responded positively, with shares climbing on the back of the earnings report. Novartis’s bet on targeted cancer therapies appears to be paying off.
Swiss Pharma Giant Novartis Bets on Breast Cancer Blockbuster as Sales Rise
